Shares of Devonian Health Group Inc. (CVE:GSD – Get Free Report) shot up 4.2% during mid-day trading on Thursday . The company traded as high as C$0.25 and last traded at C$0.25. 44,980 shares were traded during mid-day trading, an increase of 124% from the average session volume of 20,061 shares. The stock had previously closed at C$0.24.
Devonian Health Group Price Performance
The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The firm has a market cap of C$37.06 million, a PE ratio of -12.50 and a beta of 1.28. The stock has a 50 day simple moving average of C$0.20 and a 200-day simple moving average of C$0.18.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- Earnings Per Share Calculator: How to Calculate EPS
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What is a Bond Market Holiday? How to Invest and Trade
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
